Try our beta test site

Registry on Hypomethylating Agents in Myeloid Neoplasms

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Arbeitsgemeinschaft medikamentoese Tumortherapie
Information provided by (Responsible Party):
Arbeitsgemeinschaft medikamentoese Tumortherapie Identifier:
First received: May 7, 2012
Last updated: May 25, 2016
Last verified: May 2016
This Patient Registry is set up to collect real-world experience in the management of patients with myelodysplastic syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or elderly patients with Acute myeloid leukemia (AML) ineligible for high dose chemotherapy, treated with hypomethylating agents in Austria. This registry will collect data in a retrospective as well as in a prospective manner at various sites in Austria. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

Condition Intervention
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Other: non interventional

Study Type: Observational
Official Title: Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelominocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)

Resource links provided by NLM:

Further study details as provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

Primary Outcome Measures:
  • Response evaluation [ Time Frame: up to 10 years ]
    hematological response, marrow response, cytogenetic response (if data is available), quantification of reduced need for transfusions, median response duration

  • Overall survival [ Time Frame: up to 10 years ]

Secondary Outcome Measures:
  • Documentation of adverse events and toxicities [ Time Frame: up to 10 years ]
  • Number of treatment cycles [ Time Frame: up to 10 years ]
    inckusive days of treatment and dosage of azacitidine

  • Number and reasons of dose reductions [ Time Frame: up to 10 years ]
  • Uni/multivariate analysis of various factors known or thought to influence overall survival in order to establish prognostic markers [ Time Frame: up to 10 years ]
  • Establishment of a prognostic score specific for patients treated with azacitidine [ Time Frame: up to 10 years ]

Biospecimen Retention:   Samples With DNA
Biospecimen are collected prospectively on d1 of each cycle and in some cases also between the azacitidine cycles, after written informed consent has been provided. The aim is to establish a biobank of patient samples from patients treated with azacitidine, in order to have a meeningfull set of samples for future analysis of methylationstatus or mutationstatus of relevant genes, as well as to study potential changes in certain cellular subsets during and after treatment with azacitidine.

Estimated Enrollment: 1000
Study Start Date: February 2009
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Hypomethylating Agents
Patients treated with hypomethylating agents
Other: non interventional


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with MDS, CMML, and AML, who begin with or already have received treatment with VIDAZA

Inclusion Criteria:

  • Patients with MDS, CMML, and AML
  • Who begin with or already have received treatment with VIDAZA®
  • Who are willing to provide informed consent

Exclusion Criteria:

  • Due to the non-interventional design of this program there are no specific exclusion criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01595295

Contact: Richard Greil, MD +43 662 4482 ext 2879
Contact: Lisa Pleyer, MD +43 662 4482 ext 58271

LKH Feldkirch Recruiting
Feldkirch, Austria, 6807
LKH Fürstenfeld Recruiting
Fürstenfeld, Austria, 8280
Universitätsklinik für Innere Medizin V Recruiting
Innsbruck, Austria, 6020
LKH Leoben Recruiting
Leoben, Austria, 8700
AKH Linz Recruiting
Linz, Austria, 4021
Universitätsklinik für Innere Medizin III Universitätsklinik für Innere Medizin III der PMU Salzburg Recruiting
Salzburg, Austria, 5020
Klinikum Wels Grieskirchen Recruiting
Wels, Austria, 600
Krankenhaus Hietzing Recruiting
Wien, Austria, 1130
Hanusch Krankenhaus Recruiting
Wien, Austria, 1140
Wilhelminenspital Wien Recruiting
Wien, Austria, 1160
Sponsors and Collaborators
Arbeitsgemeinschaft medikamentoese Tumortherapie
Principal Investigator: Richard Greil, MD Universitätsklinik für Innere Medizin III der PMU Salzburg
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Arbeitsgemeinschaft medikamentoese Tumortherapie Identifier: NCT01595295     History of Changes
Other Study ID Numbers: AGMT_HMA Register
Study First Received: May 7, 2012
Last Updated: May 25, 2016

Keywords provided by Arbeitsgemeinschaft medikamentoese Tumortherapie:

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Neoplasms by Histologic Type
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Myelodysplastic-Myeloproliferative Diseases processed this record on March 22, 2017